“…Although the medical management of fibrotic ILDs has traditionally been limited to those patients specifically with idiopathic pulmonary fibrosis, the FDA approved the expansion of nintedanib for the broader category of progressive fibrosing ILD in 2020, after it showed efficacy in this patient population 8 . Although this might ultimately allow a simplification of our current imaging classification system, differentiating the appropriate disease pattern is still currently required for both diagnostic and prognostic purposes, and Oscarelli et al 9 and Adams et al 10 provide reviews of autoimmune ILDs and idiopathic ILDs, respectively.…”